Markets
Superstars
Analyst Estimates
Alerts
Screeners
Subscribe
Calendar
ETFs
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
Explore
FAQs
Widgets
More
Search stocks
IND
USA
USA
USA
×
Close
IND
USA
Stocks
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Stocks
Adma Biologics Inc
Swot
Adma Biologics Inc SWOT Analysis: Strengths, Weakness, Opportunity, and Threats
Adma Biologics Inc has 31 Strengths, 2 Weaknesses, 1 Opportunities and 2 Threats. The SWOT product gives you a quick x-ray of a stock's outlook and potential
Add SWOT widget to your site/app
Strengths
(31)
Weakness
(2)
Opportunity
(1)
Threats
(2)
Others
(3)
Best results last week in YoY net profit and revenue growth
30 Day SMA crossing over 200 Day SMA, and current price greater than open
Companies with 10% increase in share price over three months, with rising net profit growth
Turnaround Potential (DVM)
High Normalized Momentum Score
Consistent Highest Return Stocks over Five Years - Nifty500
Strong Momentum: Price above short, medium and long term moving averages
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Rising Net Cash Flow and Cash from Operating activity
Relative Outperformance versus Industry over the Quarter (3 Months)
Relative Outperformance versus Industry over 1 Year
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 10 Years
High Momentum Scores (Technical Scores greater than 50)
Good quarterly growth in the recent results
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Increasing profits every quarter for the past four quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Stock gained more than 20% in one month
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Increasing profits every quarter for the past 4 quarters
Top Gainers
RSI indicating price strength
Volume Shockers
High Volume, High Gain
Highest Recovery from 52 Week Low
Stocks Outperforming their Industry Price Change in the Quarter
PE higher than Industry PE
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Forecaster Consensus Estimates: Stocks with Strong Buy Calls from Analysts
Mutual Funds Decreased Shareholding in Past Month
MFs decreased their shareholding last quarter
Promoters increasing shareholding QoQ
Average Financial Performers - Stocks with Medium Trendlyne Durability Score versus Benchmarks
Average Bullish Trend - Stocks with Medium Trendlyne Momentum Score versus Benchmarks
